A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

Recruiting now · Phase 1/Phase 2

Conditions studied: mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostate Cancer

In brief

This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)

Key facts

Study ID
NCT06785636
Run by
Pathos AI, Inc.
People needed
120
Starts
2025-02-07
Expected to finish
2029-04-30
Last updated by the study team
2026-06-10

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.